The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Azathioprine for Long-Term Maintenance of Remission in Autoimmune Hepatitis
Open accessAbstract
BACKGROUND: In most patients with autoimmune hepatitis, remission can be maintained with prednisolone, usually in combination with azathioprine, but the majority of patients have a relapse when treatment is stopped and therefore require long-term therapy. Because prolonged corticosteroid therapy may have serious toxic effects, in 1984 we undertook a controlled trial of maintenance therapy with azathioprine alone. None of the 25 patients in that trial had relapses during the follow-up period of one year. We have now followed these 25 patients for 10 years and have treated an additional 47 patients in a similar manner. METHODS: The 72 patients (median age, 47 years; range, 14 to 71) had been in complete remission for at least one year with 5 to 15 mg of prednisolone per day and 1 mg of azathioprine per kilogram per day. The dose of azathioprine was increased to 2 mg per kilogram per day, and the prednisolone was gradually withdrawn. Remission was defined as the absence of symptoms suggestive of a relapse and serum globulin and aspartate aminotransferase concentrations within the normal range, with or without a liver biopsy showing only minimal inflammation. RESULTS: Sixty patients (83 percent) remained in remission while receiving azathioprine alone for a median of 67 months (range, 12 to 128). Of 48 follow-up liver biopsies in 42 patients, 45 showed inactive or minimal disease, and 3 showed moderate disease (2 after one year of therapy and 1 after eight years). After the prednisolone had been withdrawn, 26 patients lost their cushingoid facies, and 32 patients lost weight (median loss, 6.4 kg; range, 1.5 to 22.3). The most common adverse effect was arthralgia (in 38 patients). With the higher dose of azathioprine, four patients had myelosuppression, defined as a decrease in the leukocyte and platelet counts to less than 4000 and 150,000 per cubic millimeter, respectively. Two of these patients (both with pancytopenia) relapsed when the azathioprine was withdrawn; in the other two, remission was maintained with the resumption of prednisolone. Lymphopenia developed in 32 of 56 patients treated with 2 mg of azathioprine per kilogram per day for more than two years. During follow-up, nine patients died: one of liver failure and eight of causes not directly related to their liver disease. CONCLUSIONS: Many patients with autoimmune hepatitis who have been in complete remission for at least one year with prednisolone and azathioprine can remain in remission with a higher dose of azathioprine alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weinshilboum, R. M., & Sladek, S. L. (1980) · PubMed · Cited by 1,195
Meeting report: International autoimmune hepatitis group
Johnson, P. J., & McFarlane, I. G. (1993) · Hepatology · doi:10.1002/hep.1840180435 · Cited by 1,090
Self-citationSoloway, R. D., Summerskill, W. H. J., Baggenstoss, A. H., Geall, M. G., Gitnick, G. L., Elveback, L. R., & Schoenfield, L. J. (1972) · Gastroenterology · doi:10.1016/s0016-5085(19)33223-8 · Cited by 779
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
Lennard, L., Lilleyman, J. S., Van Loon, J., & Weinshilboum, R. M. (1990) · The Lancet · doi:10.1016/0140-6736(90)91745-v · Cited by 651
Lennard, L., Van Loon, J. A., & Weinshilboum, R. M. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.119 · Cited by 593
Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic Hepatitis
COOK, G. C., MULLIGAN, R., & SHERLOCK, S. (1971) · QJM · doi:10.1093/oxfordjournals.qjmed.a067264 · Cited by 564
CONTROLLED TRIAL OF PREDNISONE AND AZATHIOPRINE IN ACTIVE CHRONIC HEPATITIS
Murray-Lyon, I., Stern, R. B., & Williams, R. (1973) · The Lancet · doi:10.1016/s0140-6736(73)92125-9 · Cited by 468
Self-citationDonaldson, P. T., Doherty, D. G., Hayllar, K. M., McFarlane, I. G., Johnson, P. J., & Williams, R. (1991) · Hepatology · doi:10.1002/hep.1840130415 · Cited by 389
Self-citationSilman, A. J., Petrie, J., Hazleman, B., & Evans, S. J. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.12.988 · Cited by 276
Relapse Following Treatment Withdrawal in Patients with Autoimmune Chronic Active Hepatitis
Hegarty, J. E., Nouri Aria, K. T., Portmann, B., Eddleston, A. L. W. F., & Williams, R. (1983) · Hepatology · doi:10.1002/hep.1840030510 · Cited by 174
Self-citationThe Pharmacology and Metabolism of the Thiopurine Drugs 6-Mercaptopurine and Azathioprine
Scoik, K. G. V., Johnson, C. A., & Porter, W. R. (1985) · Drug Metabolism Reviews · doi:10.3109/03602538508991433 · Cited by 153
McFarlane, B. M., McSorley, C., Vergani, D., McFarlane, I. G., & Williams, R. L. (1986) · Journal of Hepatology · doi:10.1016/s0168-8278(86)80026-5 · Cited by 141
Self-citationStellon, A. J., Keating, J. J., Johnson, P. J., McFarlane, I. G., & Williams, R. L. (1988) · Hepatology · doi:10.1002/hep.1840080414 · Cited by 134
Self-citationNaber, A. H. J., van Haelst, U., & Yap, S. H. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90916-y · Cited by 122
Nodular Regenerative Hyperplasia of the Liver Graft After Liver Transplantation
Gane, E. J., Portmann, B. C., Saxena, R., Wong, P. Y. N., Ramage, J. K., & Williams, R. L. (1994) · Hepatology · doi:10.1002/hep.1840200114 · Cited by 107
Self-citationDoherty, D. G., Vaughan, R. W., Donaldson, P. T., & Mowat, A. P. (1992) · Human Immunology · doi:10.1016/0198-8859(92)90085-2 · Cited by 100
Czaja, A. J., Beaver, S. J., & Shiels, M. T. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90862-6 · Cited by 89
Wang, K. K., Czaja, A. J., Beaver, S. J., & Go, V. L. W. (1989) · Hepatology · doi:10.1002/hep.1840100110 · Cited by 73
RANDOMISED CONTROLLED TRIAL OF AZATHIOPRINE WITHDRAWAL IN AUTOIMMUNE CHRONIC ACTIVE HEPATITIS
Stellon, A. J., Portmann, B. C., Hegarty, J., & Williams, R. L. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91329-7 · Cited by 64
Self-citation
Cited by
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Diagnosis and management of autoimmune hepatitis
Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., & Vierling, J. M. (2010) · Hepatology · doi:10.1002/hep.23584 · Cited by 1,442
EASL Clinical Practice Guidelines: autoimmune hepatitis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.030 · Cited by 1,245
Human autoimmune diseases: a comprehensive update
Wang, L., Wang, F., & Gershwin, M. E. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12395 · Cited by 1,168
Mack, C. L., Adams, D., Assis, D. N., Kerkar, N., Manns, M. P., Mayo, M. J., Vierling, J. M., Alsawas, M., Murad, M. H., & Czaja, A. J. (2020) · Hepatology · doi:10.1002/hep.31065 · Cited by 983
“Biochemical remission is induced with the standard glucocorticoid and AZA regimen, and then the dose of AZA is adjusted up to 2 mg/kg daily as the dose of prednisone or prednisolone is reduced to the lowest dose possible or fully withdrawn.(398,399) Patients intolerant of AZA can be treated with MMF, or in adults, low…”
Method
Metadata
- Authors
- Johnson, P. J., McFarlane, I. G., & Williams, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1995-10-12
- Volume
- 333
- Issue
- 15
- Pages
- 958-963
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2328996992
- Cited by
- 382
- References
- 19
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.